An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years  by Hodson, Margaret E. et al.
(2008) 537–542
www.elsevier.com/locate/jcfJournal of Cystic Fibrosis 7An international/multicentre report on patients with cystic fibrosis (CF)
over the age of 40 years
Margaret E. Hodson a,⁎, Nicholas J. Simmonds a, Warren J. Warwick b, Elizabeth Tullis c,
Carlo Castellani d, Baroukh Assael d, John A. Dodge e, Mary Corey f,
For the International Study of Aging in Cystic Fibrosis
a Department of Cystic Fibrosis, Royal Brompton Hospital/Imperial College, London SW3 6NP, UK
b Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN55455, USA
c Adult Cystic Fibrosis Program, St Michael's Hospital, University of Toronto, Ontario Canada M5B 1W8
d Regional Cystic Fibrosis Centre, Ospedale Civile Maggiore, 37126, Verona, Italy
e Department of Child Health, University of Wales Swansea, UK
f Hospital for Sick Children, University of Toronto, Canada
Received 19 March 2008; received in revised form 30 May 2008; accepted 21 June 2008
Available online 19 August 2008Abstract
Background: The lifespan of patients with cystic fibrosis (CF) is increasing significantly. The objective of this international pilot study was to
study the characteristics of these long-term survivors.
Methods: Four centres with large CF clinics from London (UK), Minneapolis (USA), Toronto (Canada) and Verona (Italy) identified 366 patients
who had survived 40years and longer.
Results: At all centres males survived longer than females. There were more pancreatic sufficient patients in Verona (60%) and Toronto (40%) than
in London (16%) and Minneapolis (21%). The percentage of ΔF508 homozygous patients varied between 47% in London and 45% in
Minneapolis to only 26% in Toronto and 9% in Verona.
Average FEV1 and BMI values of the surviving population appeared to stabilise after 40years of age. FEV1 was on average 12% higher in
patients who were pancreatic sufficient (p N 0.0001). There was no difference in survival between the centres. The overall median survival after
the age of 40 was 13years. The estimated annual death rate was approximately 3.4% from the age of 40–60years.
Conclusions: Significant numbers of patients are now surviving to 40years or more, and it is hoped that an in-depth study of these patients may
identify the factors contributing to longer survival.
© 2008 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Longevity1. Introduction
The lifespan of patients with cystic fibrosis (CF) has been
steadily increasing in all countries where it has been measured,
and there are good epidemiological reasons for believing that
this trend, which has been apparent for several decades, will
continue even in the absence of novel treatments directed⁎ Corresponding author. Department of Cystic Fibrosis, Royal Brompton
Hospital, Sydney Street, London SW3 6NP, UK. Fax: +44 020 7351 8052.
E-mail address: m.hodson@imperial.ac.uk (M.E. Hodson).
1569-1993/$ - see front matter © 2008 Published by Elsevier B.V. on behalf of Eu
doi:10.1016/j.jcf.2008.06.003toward correcting the basic CF genetic and molecular defect(s)
[1,2].
Death from CF during childhood is now a rarity in the UK
and other industrialised countries, and well over 95% of CF
children can expect to enter adult life, with a corresponding
need for appropriate medical services [3].
Survival beyond the fourth decade presents new questions and
potential problemswhich are still being formulated. The effects of
CF on the aging process, and vice versa, are not known, apart
from a preliminary international study of malignancy [4]. Other
diseases with a prevalence closely linked to age, such as arterialropean Cystic Fibrosis Society.
Table 1
CF patients over 40 years of age (1979–2004) — basic demographics
London Minnesota Toronto Verona Total
Last seen
1979–2002 25 26 40 9 100
2003–2004 90 63 75 38 266
Total 115 89 115 47 366
Sex a
Female 48 (41.7) 31 (34.8) 47 (40.9) 21 (44.7) 147
Male 67 (58.3) 58 (65.2) 68 (59.1) 26 (55.3) 219
N 115 89 115 47 366
Age at diagnosis b
Adult ≥18 years 32 (27.8) 35 (39.8) 44 (38.3) 26 (63.4) 137
Child b18 years 83 (72.2) 53 (60.2) 71 (61.7) 15 (36.6) 222
N 115 88 115 41 359
Pancreatic status b
Sufficient 19 (16.5) 19 (21.4) 50 (43.5) 28 (59.6) 116
Insufficient 96 (83.5) 70 (78.6) 65 (56.5) 19 (40.4) 250
N 115 89 115 47 366
Genotype c
ΔF508/ΔF508 41 (42.7) 35 (45.4) 28 (26.2) 4 (8.7) 108
ΔF508/0 51 (53.1) 34 (44.2) 55 (52.3) 23 (50) 164
O/O 4 (4.2) 8 (10.4) 23 (21.5) 19 (41.3) 54
N 96 77 107 46 326
dSymptoms at diagnosis
Chest only 41 (35.6) 3 (5.3) 41 (35.7) 16 (34) 101
Gut only 44 (38.2) 4 (7.0) 13 (11.3) 2 (4.2) 63
Both 13 (11.3) 2 (3.5) 51 (44.3) 5 (10.6) 71
Unknown 1 (0.8) 24 (42.1) 9 (7.8) 19 (12.8) 53
Family history 18 (15.7) 26 (45.6) 6 (5.2) 6 (12.8) 56
N 115 89 116 47
No. (%) N=Number on whom data was available.
0=a recognised CF allele other than ΔF508.
a p=0.0002, Chi-square test (1df) of equal proportions for male and female.
b pb0.001, Chi-square test (3df) of equal proportions in the 4 sites.
c pb0.001, Chi-square test (6df) of equal proportions in the 4 sites.
d Some patients had more than one.
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disease, could in theory be more or less common in age-matched
CF patients — who usually have, for example, low cholesterol
levels but an increased risk of diabetes. Understanding the nature
of such interaction between diseases could shed important light on
the mechanisms and control of both CF and other conditions.
The International Study ofAging inCystic Fibrosiswas set up to
address these and other issues, and to share the limited experience
of caring for relatively elderly CF patients with other professionals
[5]. A preliminary search among interested CF centres in 2003
identified more than 1800 patients who were still alive beyond the
age of 40 [6]. It was further evident that the numbers of such
patients would escalate rapidly over the next decade. The current
actuarial mean survival in countries with well developed CF
services being about 35–40years for both sexes combined, and
increasing year on year [7]. Male and female patients in the United
Kingdom who were alive in 2003 at the age of 30years, had an
estimated mean expectation of dying by 52.7 and 49.4years
respectively [7]. In the Canadian Patient Data Registry, the
percentage of patients over age 40 has steadily doubled every
5years, from less than 0.2% in 1977 to 6.7% in 2002. At this rate,
20% of Canadian CF patients will be over 40years of age by 2010
[8]. Similar aging patterns are seen in other western countries.
As a starting point it was therefore decided to look at
individuals over 40years of age in more detail, to try to identify
the factors which had contributed to their better survival,
whether genetic, socioeconomic or therapeutic, and to discover
whether later complications of CF could be anticipated, and
whether they would experience a relatively greater or lesser risk
of common age-associated disorders. The experience of four
large CF centres, two in Europe (London and Verona) and two
in North America (Minneapolis and Toronto), has now been
analysed. Data were obtained from existing medical records and
are presented in this report, which provides baseline data for
planned prospective and more detailed enquiries.
2. Methods
Four CF centres, Royal Brompton Hospital, London, Cystic
Fibrosis Center, University of Minnesota, Minneapolis, USA, St
Michael's Hospital, Toronto, Canada and CF Centre, Verona,
Italy contributed to this study. Clinical data from CF patients in
each centre who had reached 40years of age by 31/12/2004 was
anonymised and submitted to Toronto for analysis (by MC).
Patients were grouped as seen in 03/04, i.e. alive at the end of
the study, or last seen before 2003/2004— i.e. patients who had
died over 40years of age prior to 2003/2004. The following data
was collected:
• date of birth,
• sex,
• genotype,
• pancreatic sufficiency or insufficiency,
• sputum microbiology (when last seen in the 2003/2004
group)
• forced expiratory volume in one second (FEV1)
• Body Mass Index (BMI).The following events and complications were also recorded:
◦ lung transplantation
◦ diabetes
◦ major haemoptysis
◦ allergic bronchopulmonary aspergillosis
◦ portal hypertension
◦ pneumothorax.
The definitions of diabetes, major haemoptysis, allergic
bronchopulmonary aspergillosis, portal hypertension and pneu-
mothorax were centre-specific, in that these conditions were
diagnosed as present by the patient's clinician and recorded as
such in the case file.
Lung function and BMI were summarized in box plots at
5year intervals, using the measurement date nearest each
individual's birthday. Repeated measures regression analysis
was conducted using longitudinal measures on individual sub-
jects to estimate average rates of change over time in FEV1 and
Fig. 1. CF patients over 40 years (2003–2004 data) showing FEV1 at 5 yearly
intervals.
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compare the proportion of patients reported with specific
complications and the proportion positive for specific lung
infections. Kaplan Meier survival curves after the age of
40years were computed, and compared using the log rank test.
Significance was taken as p b 0.05.
3. Results
The numbers of patients who had died over the age of 40,
and last seen in London, Minnesota, Toronto and Verona were
25, 36, 40 and 9 respectively, and patients seen in 2003–2005,
(i.e. still alive), were 90, 63, 75 and 38. London, Minnesota,
Toronto and Verona therefore contributed data for 115, 89, 115,
and 47 patients respectively. This paper therefore reports on a
total of 366 patients from the four centres. Not all data were
available on all patients but this is indicated by n numbers in the
tables.
There were no major differences in the analysis of patients
seen in 2003–2004 when compared with the whole group who
passed the age of 40years since 1979 (Table 1). Age distribution
by site was similar with the median in the mid-40s and the oldest
subjects in the 60s. There were group differences in percentage
diagnosed as children (p = 0.001), most in London, (72%) least
in Verona (36%), similar in Toronto (62%) and Minnesota
(60%). The reason for diagnosis (Table 1) varied between sites.
In London the most frequent features were respiratory and
gastrointestinal symptoms, whereas in Minneapolis they were
recorded as family history or unknown. In all centres more males
had survived to 40years than females (p = 0.0002), and the sex
ratio was not different between centres (p = 0.7). There were
many more pancreatic sufficient patients (Table 1) in Verona
(59.6%) and Toronto (40.5%) than in London and Minneapolis
(16.5 and 21% respectively) (p b 0.001). The incidence of
mutations ΔF508/ΔF508 varied significantly (Table 1), beingTable 2
CF patients over 40 years of age (1979–2004) — major events and
complications
London Minnesota Toronto Verona Total
Lung transplantation 22 (19.1) 10 (11.2) 21 (18.3) 1 (2.1) 54
N=115 N=89 N=115 N=47 N=366
Diabetes 32 (27.8) 19 (21.4) 39 (35.3) 10 (21.3) 100
N=115 N=89 N=115 N=47 N=366
Major haemoptysis 19 (16.5) 2 (2.2) 8 (7.0) 11 (23.4) 40
N=115 N=89 N=115 N=47 N=366
Allergic
bronchopulmonary
aspergillosis
13 (11.3) 3 (3.4) NA 7 (14.9) 23
N=115 N=89 NA N=47 N=251
Portal hypertension 5 (4.3) 0 (0) 9 (7.9) 0 (0) 29
N=115 N=89 N=115 N=47 N=366
Pneumothorax 15 (13.0) 4 (4.5) 3 (2.6) 4 (8.5) 26
N=115 N=89 N=115 N=47 N=366
Lung function: FEV1
mean (SD)
53 (27) 55 (28) 58 (24) 55 (31) 55 (27)
N=115 N=89 N=115 N=47 N=366
Nutrition: BMI
mean (SD)
22 (3.3) 24 (3.2) 24 (3.6) 22 (3.0) 23 (4.0)
N=103 N=63 N=82 N=35 N=283
No. (%) N=number on whom data was available. NA=not available.42.7% in London, 45.4% in Minneapolis but only 26.2% in
Toronto and 8.7% in Verona (p b 0. 001). Mean lung function
and BMI for those who were observed at age 40 was remarkably
similar across centres. Not all patients were observed at age 40
since some were diagnosed later or transferred from another
centre.
More lung transplants were carried out in London and
Toronto than in the other centres (Table 2, p = 0.02). The
incidence of CF-related diabetes was not significantly different
in the 4 centres (p = 0.13). Major haemoptysis was seen more
frequently in London and Verona (p = 0.002). Allergic
bronchopulmonary aspergillosis (Table 2) was higher in Verona
and London than in Minneapolis (p = 0.05) but data were not
available for Toronto. Portal hypertension was more frequent in
Toronto than London, and unexplainably not seen in Minnesota
and Verona (Table 2). Pneumothorax was more commonly seen
in London (13%) than elsewhere (Table 2) (p = 0.01). Only
London had survival data on post-pneumothorax survival which
was a mean of 122 months.
3.1. Microbiology (2003–2004 group)
Information on pathogens isolated from the sputum was
available for 259 patients for the last year of study. London,Fig. 2. CF patients over 40 years (2003–2004 data) showing BMI at 5 yearly
intervals.
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ginosa 77.8%; 70.7%; 46.7% and 55.6% respectively (p =
0.0002); Staphylococcus aureus 57.8%; 20.7%; 22.7% and
61.1% respectively (p b 0.0001);Haemophilus influenza 18.9%;
0%; 10.7%, 22.2% respectively (p = 0.002), Burkholderia
cepacia 6.7%; 1.7%; 22.7% and 5.6% respectively (p = 0.0002);
Stenotrophomonas maltophilia 1.1%; 1.7%; 9.3% and 22.2%
respectively (p b 0.0001); Aspergillus fumigatus 2.2%, 36.2%,
30,7% and 0% respectively (p b 0.0001); Mycobacterium
tuberculosiswas only isolated from one patient in London, none
was recorded at the other centres.
3.2. Lung function
FEV1 is shown in Fig. 1 plotted at 5year intervals, and shows
that the distribution of lung function values are remarkably similar
at ages 40 to 55, with slightly higher values at aged 60 and 65
reflecting a very small number of survivors. FEV1 was on the
average 12% predicted higher in the pancreatic sufficient than the
insufficient patients (p b 0.0001). The average values of FEV1
were higher in Verona but there was no significant difference in
FEV1 across site or age group when pancreatic insufficiency/
sufficiency was included in the repeated measures regression
model. FEV1 was consistently 3% predicted lower in females
compared with males but this was not statistically significant (p =
0.11). In repeatedmeasures analysis restricted to ages 35–55years
there was a consistent negative effect over time that did not differ
across centres, reflecting a rate of change in FEV1 of − 0.4%
predicted/year (p = 0.02). This reflects the average longitudinal
rate of decline in individuals, but through mortality selection the
average FEV1 in box plots appeared constant across the ages.
3.3. Body Mass Index (BMI)
The average BMI values (Fig. 2) were 22–23 at all ages with
a small inter-quartile range up to the age of 55years, i.e. the
majority of patients having a healthy BMI in the 19–25 range.
Toronto and Minnesota had higher BMI than London and
Verona (p = 0.0001). Female BMI was on the average 1.3 points
lower than males (p b 0.001) and pancreatic sufficient patients
had a BMI on average 2.6 points higher than PI patients. Unlike
FEV1 there was no longitudinal decline in BMI, in the analysis
of repeated measures. In fact there was a significant averageFig. 3. All patients over 40 years of age, survival from the age of 40 years.increase in BMI of 0.1 units/year (p = 0.001), indicating that
long time adult survivors have well-maintained or improved
nutritional status as they get older.
3.4. Survival
There was no significant difference between the survival
curves of the four centres (log rank test p = 0.8). The overall
median survival after the age of 40 was 13years, i.e. to 53years
of age, and the survival curves were quite linear (Fig. 3).
Survival analysis for the combined four centres gave an
estimated death rate of approximately 3.4%/annum from the
age of 40–60years (based on the estimated 32% survival) and
68% mortality by the age of 60years.
4. Discussion
Patients with CF are surviving longer. We have reported on
detailed records of 366 who have survived to more than
40years. More males than females survived in all four centres.
In London the patients were diagnosed younger, and in Verona
older. This may be because in Verona there were more patients
with pancreatic sufficiency (which is known to be associated
with late diagnosis) [9], whereas symptoms of malabsorption
are a common method of presentation leading to diagnosis in
childhood. A higher proportion of CF patients in Southern
Europe are pancreatic sufficient, and the high incidence of
pancreatic sufficiency in Toronto (40%) may reflect the large
number of immigrants from Mediterranean countries, particu-
larly Italy. In contrast, Minneapolis, with a population largely
derived from Northern Europe, is genetically and clinically
much more similar to London.
There was wide variation in the frequency of complications.
In the case of allergic bronchopulmonary aspergillosis and
portal hypertension there is difficulty in getting agreed criteria
in different decades. We have therefore used a ‘clinical
diagnosis’ by the clinician.
The prevalence of diabetes was highest in Toronto, but overall
the range was from 21–35%. The reason for the increased risk of
developing CF-associated diabetes in Toronto is not clear, but
possible contributory factors may be the historical emphasis on a
high-calorie diet in Toronto CF clinics, which is also reflected in
the higher BMI [7]. There is good evidence that maintenance of
good nutritional status in children with CF correlates positively
with the clinical condition of CF adults [11], and with survival
[10], but a higher risk of developing diabetesmay be an unwanted
consequence. Other explanations could be the higher incidence of
post-transplant patients on immunosuppressants and because
Toronto screens annually using OGTT. Other centres screened,
but not all used this method.
The definition of major haemoptysis is imprecise, but it
appears to be higher in London and Verona (16 and 23%
respectively) compared with Minnesota and Toronto (2.2 and
7% respectively). Pneumothorax was more common in London
at 13% than in the other centres. In two recent papers it has been
reported to be associated with a poor prognosis and an increased
risk of dying within 2years [12,13]. In the patients reported here,
541M.E. Hodson et al. / Journal of Cystic Fibrosis 7 (2008) 537–542average survival after an episode of pneumothorax was much
better in London, 5 patients who have died survived between 60
and 320months after their first pneumothorax, and a further 6 are
still alive up to a median of 158 months.
Microbiology is only presented for the 2003–2004 period
but there were striking differences which may represent
geographical difference in prevalence. The higher rate of
B. cepacia in Toronto is well known [14]. The lower rate of
pseudomonas in Toronto may reflect a more frequent use of
inhaled tobramycin, and some pseudomonas may have been
replaced by B. cepacia.
The apparent stability of cross-sectional lung function and
BMI after the age of 35years was striking, and this appears to be a
new observation which applied to all centres. The mean
longitudinal decline in FEV1 of 0.4% predicted/year was small
by any standards, and reflects a relative stability in these older
patients. There was no evidence of longitudinal BMI decline, and
average values indicated that these patients are able to maintain a
healthy weight. Survival was similar between the four centres at
50years, in spite of an increased prevalence of B. cepacia in
Toronto. Verona had less ΔF508/ΔF508 and less pancreatic
insufficiency and may have a survival advantage at 60years.
Based on the age-specific death rates in this study population,
patients who reached 40years of age have a 50% chance of
reaching 53years of age, and a 35% chance of reaching 60. Older
patients aware of the study have found this observation
encouraging, however, this contrasts with an earlier estimate,
based on assumptions, of a 54% chance of survival to age 60years
[6]. The improving outlook for each successive cohort of patients
may in fact make the more favourable prediction more likely for
patients who are currently approaching their 5th decade.
London, Minnesota and Toronto are lung transplant centres,
so it is not surprising that they have a higher proportion of
patients who had received transplanted lungs. Lung transplant
rates are high in Toronto even though a large percentage of
candidates are infected with B. cepacia which is associated with
a reduced post-transplant survival [15].
These data provide a background for more detailed investiga-
tions. The crucial question is why do some patients survive longer
than others? The available information indicates that it can only in
part be related to the CFTR genotype: more than 40% of long
survivors in London and Minnesota were homozygous for the
“severe” ΔF508 mutation. The influence of modifier genes at
other loci may be important [16]; for example, genes which
modify inflammatory responses to infection [17,18].
The importance of non-genetic factors in determining the
clinical severity of CF was highlighted by a recent report of a pair
of genetically proven identical female twins. At the age of 40years
their FEV1 and body weights were strikingly different (88% v
29% predicted, and 66 v 55kg respectively), although the twin
with the worse lung function had always had the lower body
weight [19]. How important are social, economic and psycholo-
gical factors [20], including adherence to therapeutic regimens? It
is clear that the improved survival seen in the whole CF
population maybe due in largemeasure to better medical care, but
which components of that package of care have been most
important? Most long survivors will have benefited fromspecialist centre care, which included frequent surveillance,
intravenous antibiotics for exacerbation of pulmonary infection,
lung clearance measures, inhaled antibiotics and nutritional
advice and support. The importance of early childhood nutrition
has been shown previously [10,11].
Mean life expectancy for CF children was less than 15years
when these patients were born. Are we reporting individuals at
the upper end of a multifactorial genetic spectrum of disease and
longevity which has only become apparent because death from
CF in early life has been largely eliminated, or are there
identifiable environmental factors which could be reproduced?
If the significant factors contributing to these patients' longevity
can be identified, it may be possible to extend their benefits to
the wider population of people with CF.
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